Trimethylamine N-oxide (TMAO), high-sensitivity C-reactive protein (hs-CRP), and gut microbiota features will be assessed at baseline and 2 months ± 3 days to probe possible mechanism. In addition, the survey scales will also be tested at 1 month ± 3 days. The primary outcomes, metabolic equivalents (METS) and peak oxygen uptake (Peak VO 2), and the secondary outcomes, including other indicators of cardiorespiratory fitness (CRF), the European Quality of Life Questionnaire (EQ-5D-5L), the Seattle Angina Scale (SAQ), etc., will be assessed at baseline and 2 months ± 3 days. Based on standardized treatment, the intervention group and control group will receive SQSX and placebo for 2 months, respectively. A total of 120 participants will be randomized 1:1 into the intervention group and the control group. The study is a multi-center, randomized, double-blinded, parallel, placebo-controlled trial.
0 kommentar(er)
